Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 4
1982 3
1983 10
1984 4
1985 21
1986 15
1987 43
1988 142
1989 357
1990 529
1991 825
1992 1134
1993 1096
1994 1395
1995 1426
1996 1425
1997 1511
1998 1522
1999 1512
2000 1764
2001 1749
2002 1771
2003 1914
2004 1963
2005 2211
2006 2292
2007 2368
2008 2675
2009 2942
2010 3107
2011 3482
2012 3794
2013 3956
2014 4050
2015 4061
2016 3829
2017 3792
2018 3375
2019 3273
2020 3285
2021 2941
2022 4848
2023 4139
2024 2529
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79,890 results

Results by year

Filters applied: . Clear all
Page 1
Proteogenomic Data Integration Reveals CXCL10 as a Potentially Downstream Causal Mediator for IL-6 Signaling on Atherosclerosis.
Prapiadou S, Živković L, Thorand B, George MJ, van der Laan SW, Malik R, Herder C, Koenig W, Ueland T, Kleveland O, Aukrust P, Gullestad L, Bernhagen J, Pasterkamp G, Peters A, Hingorani AD, Rosand J, Dichgans M, Anderson CD, Georgakis MK. Prapiadou S, et al. Circulation. 2024 Feb 27;149(9):669-683. doi: 10.1161/CIRCULATIONAHA.123.064974. Epub 2023 Dec 28. Circulation. 2024. PMID: 38152968 Free article.
Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer.
Naqash AR, McCallen JD, Mi E, Iivanainen S, Marie MA, Gramenitskaya D, Clark J, Koivunen JP, Macherla S, Jonnalagadda S, Polsani S, Jiwani RA, Hafiz M, Muzaffar M, Brunetti L, Stroud CRG, Walker PR, Wang K, Chung Y, Ruppin E, Lee SH, Yang LV, Pinato DJ, Lee JS, Cortellini A. Naqash AR, et al. J Immunother Cancer. 2023 Oct;11(10):e007310. doi: 10.1136/jitc-2023-007310. J Immunother Cancer. 2023. PMID: 37852738 Free PMC article.
79,890 results
You have reached the last available page of results. Please see the User Guide for more information.